Defrance R - Search Results

1

Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.

Judde JG, Rebucci M, Vogt N, de Cremoux P, Livartowski A, Chapelier A, Tran-Perennou C, Boye K, Defrance R, Poupon MF, Bras-Gonçalves RA. Judde JG, et al. Among authors: defrance r. Int J Cancer. 2007 Apr 1;120(7):1579-90. doi: 10.1002/ijc.22364. Int J Cancer. 2007. PMID: 17205515 Free article.

2

Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro.

Giocanti N, Hennequin C, Rouillard D, Defrance R, Favaudon V. Giocanti N, et al. Among authors: defrance r. Br J Cancer. 2004 Dec 13;91(12):2026-33. doi: 10.1038/sj.bjc.6602242. Br J Cancer. 2004. PMID: 15545965 Free PMC article.

3

Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial.

Tubiana-Hulin M, Becette V, Bieche I, Mauriac L, Romieu G, Bibeau F, Macgrogan G, Bourgeois H, Chollet P, Defrance R, Spyratos F. Tubiana-Hulin M, et al. Among authors: defrance r. Anticancer Res. 2007 Jul-Aug;27(4C):2689-96. Anticancer Res. 2007. PMID: 17695434 Free article. Clinical Trial.

4

A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors.

Teixeira L, Medioni J, Garibal J, Adotevi O, Doucet L, Durey MD, Ghrieb Z, Kiladjian JJ, Brizard M, Laheurte C, Wehbe M, Pliquet E, Escande M, Defrance R, Culine S, Oudard S, Wain-Hobson S, Doppler V, Huet T, Langlade-Demoyen P. Teixeira L, et al. Among authors: defrance r. Clin Cancer Res. 2020 Feb 1;26(3):588-597. doi: 10.1158/1078-0432.CCR-19-1614. Epub 2019 Sep 26. Clin Cancer Res. 2020. PMID: 31558479

5

Assessing cancer drugs for reimbursement: methodology, relationship between effect size and medical need.

de Sahb-Berkovitch R, Woronoff-Lemsi MC, Molimard M; participates of Round Table n° 7 Giens 2009. de Sahb-Berkovitch R, et al. Therapie. 2010 Jul-Aug;65(4):373-7, 367-72. doi: 10.2515/therapie/2010042. Epub 2010 Sep 21. Therapie. 2010. PMID: 20854761 English, French.

6

Critères et méthodologie d'évaluation au remboursement des anticancéreux.

Sahb-Berkovitch Rd, Woronoff-Lemsi MC, Molimard M; les participants de la Table Ronde n°7 de Giens 2009. Sahb-Berkovitch Rd, et al. Therapie. 2010 Jul-Aug;65(4):367-72. doi: 10.2515/therapie/20010041. Therapie. 2010. PMID: 27393114 French. No abstract available.

7

Prevalence of sleep/wake disorders in persons with blindness.

Leger D, Guilleminault C, Defrance R, Domont A, Paillard M. Leger D, et al. Among authors: defrance r. Clin Sci (Lond). 1999 Aug;97(2):193-9. Clin Sci (Lond). 1999. PMID: 10409474

8

Disturbance of sleep in blindness.

Tabandeh H, Lockley SW, Buttery R, Skene DJ, Defrance R, Arendt J, Bird AC. Tabandeh H, et al. Among authors: defrance r. Am J Ophthalmol. 1998 Nov;126(5):707-12. doi: 10.1016/s0002-9394(98)00133-0. Am J Ophthalmol. 1998. PMID: 9822235

9

Therapeutic applications of melatonin and related compounds.

Defrance R, Quera-Salva MA. Defrance R, et al. Horm Res. 1998;49(3-4):142-6. doi: 10.1159/000023161. Horm Res. 1998. PMID: 9550115 Review.

10

Rapid shift in peak melatonin secretion associated with improved performance in short shift work schedule.

Quera-Salva MA, Guilleminault C, Claustrat B, Defrance R, Gajdos P, McCann CC, De Lattre J. Quera-Salva MA, et al. Among authors: defrance r. Sleep. 1997 Dec;20(12):1145-50. Sleep. 1997. PMID: 9493924

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page